Quadrant Capital Group’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $9.32M | Buy |
61,012
+1,152
| +2% | +$177K | 0.28% | 46 |
|
|
2025
Q4 | $8.25M | Buy |
59,860
+166
| +0.3% | +$21.7K | 0.25% | 50 |
|
|
2025
Q3 | $7.66M | Buy |
59,694
+2,262
| +4% | +$276K | 0.25% | 48 |
|
|
2025
Q2 | $6.95M | Sell |
57,432
-7,545
| -12% | -$850K | 0.25% | 47 |
|
|
2025
Q1 | $7.24M | Buy |
64,977
+46,877
| +259% | +$4.99M | 0.27% | 43 |
|
|
2024
Q4 | $1.76M | Buy |
18,100
+352
| +2% | +$37.5K | 0.12% | 114 |
|
|
2024
Q3 | $2.04M | Buy |
17,748
+386
| +2% | +$43.8K | 0.14% | 99 |
|
|
2024
Q2 | $1.85M | Buy |
17,362
+581
| +3% | +$58.3K | 0.14% | 102 |
|
|
2024
Q1 | $1.62M | Sell |
16,781
-84
| -0.5% | -$8.61K | 0.13% | 114 |
|
|
2023
Q4 | $1.7M | Buy |
16,865
+2,119
| +14% | +$205K | 0.15% | 100 |
|
|
2023
Q3 | $1.5M | Buy |
14,746
+634
| +4% | +$64.4K | 0.15% | 93 |
|
|
2023
Q2 | $1.42M | Sell |
14,112
-128
| -0.9% | -$12.8K | 0.14% | 97 |
|
|
2023
Q1 | $1.31M | Buy |
14,240
+3,142
| +28% | +$274K | 0.14% | 107 |
|
|
2022
Q4 | $1.01M | Buy |
11,098
+636
| +6% | +$53.6K | 0.11% | 128 |
|
|
2022
Q3 | $795K | Buy |
10,462
+1,482
| +17% | +$123K | 0.11% | 128 |
|
|
2022
Q2 | $759K | Sell |
8,980
-1,168
| -12% | -$102K | 0.1% | 146 |
|
|
2022
Q1 | $890K | Buy |
10,148
+3,038
| +43% | +$263K | 0.11% | 147 |
|
|
2021
Q4 | $622K | Sell |
7,110
-1,122
| -14% | -$93.2K | 0.07% | 180 |
|
|
2021
Q3 | $673K | Buy |
8,232
+232
| +3% | +$20.9K | 0.09% | 152 |
|
|
2021
Q2 | $730K | Buy |
8,000
+310
| +4% | +$27.6K | 0.11% | 143 |
|
|
2021
Q1 | $657K | Buy |
7,690
+512
| +7% | +$45.9K | 0.11% | 139 |
|
|
2020
Q4 | $678K | Buy |
7,178
+34
| +0.5% | +$2.97K | 0.13% | 120 |
|
|
2020
Q3 | $621K | Sell |
7,144
-744
| -9% | -$64.5K | 0.14% | 111 |
|
|
2020
Q2 | $689K | Sell |
7,888
-17,730
| -69% | -$1.53M | 0.15% | 110 |
|
|
2020
Q1 | $2.11M | Buy |
25,618
+1,982
| +8% | +$177K | 0.35% | 53 |
|
|
2019
Q4 | $2.21M | Buy |
23,636
+1,078
| +5% | +$96.7K | 0.27% | 57 |
|
|
2019
Q3 | $1.95M | Buy |
22,558
+487
| +2% | +$43.7K | 0.3% | 59 |
|
|
2019
Q2 | $2M | Buy |
22,071
+1,312
| +6% | +$111K | 0.32% | 55 |
|
|
2019
Q1 | $1.77M | Buy |
20,759
+5,440
| +36% | +$437K | 0.31% | 56 |
|
|
2018
Q4 | $1.16M | Buy |
15,319
+9,414
| +159% | +$733K | 0.31% | 55 |
|
|
2018
Q3 | $441K | Buy |
5,905
+238
| +4% | +$17.6K | 0.13% | 116 |
|
|
2018
Q2 | $368K | Sell |
5,667
-106
| -2% | -$7.32K | 0.13% | 127 |
|
|
2018
Q1 | $403K | Buy |
5,773
+465
| +9% | +$35.4K | 0.15% | 127 |
|
|
2017
Q4 | $387K | Buy |
5,308
+201
| +4% | +$15.2K | 0.15% | 123 |
|
|
2017
Q3 | $380K | Buy |
5,107
+260
| +5% | +$19.6K | 0.16% | 118 |
|
|
2017
Q2 | $348K | Buy |
4,847
+485
| +11% | +$34.4K | 0.15% | 115 |
|
|
2017
Q1 | $282K | Buy |
4,362
+1,915
| +78% | +$128K | 0.12% | 140 |
|
|
2016
Q4 | $153K | Sell |
2,447
-580
| -19% | -$37.6K | 0.08% | 192 |
|
|
2016
Q3 | $205K | Buy |
3,027
+397
| +15% | +$28.9K | 0.13% | 133 |
|
|
2016
Q2 | $186K | Buy |
2,630
+666
| +34% | +$46K | 0.13% | 134 |
|
|
2016
Q1 | $121K | Buy |
1,964
+1,184
| +152% | +$80.5K | 0.08% | 199 |
|
|
2015
Q4 | $57K | Buy |
780
+133
| +21% | +$10.6K | 0.04% | 358 |
|
|
2015
Q3 | $52K | Sell |
647
-77
| -11% | -$6.85K | 0.04% | 401 |
|
|
2015
Q2 | $60K | Buy |
+724
| New | +$66.4K | 0.04% | 383 |
|
Other funds holding NVS
Quadrant Capital Group's NVS Position: Q1 2026 in Review
Quadrant Capital Group increased its Novartis (NVS) stake by 1.9% in Q1 2026, buying an estimated $177K and bringing the position to 61,012 shares worth $9.32M. The position accounts for 0.28% of the portfolio, ranked #46.
Quadrant Capital Group first reported a position in NVS in Q2 2015 and has held it in 44 quarters since. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.
- Quadrant Capital Group held 61,012 shares of Novartis worth $9.32M as of Q1 2026.
- Quadrant Capital Group bought 1,152 Novartis shares in Q1 2026, an estimated $177K.
- Novartis made up 0.28% of Quadrant Capital Group's portfolio in Q1 2026, its #46 holding.
- Quadrant Capital Group first reported a position in Novartis in Q2 2015 and has held it in 44 quarters since.
- 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.
Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.